The initiation of coverage by Scotiabank with a Sector Outperform rating and a high price target of $35 is likely to generate positive investor sentiment towards NewAmsterdam Pharma. This bullish outlook from a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.